ATE199319T1 - Pharmazeutische zusammensetzung mit therapeutischer wirkung auf die neuronalen schädigungen in aids-patienten, enthaltend als wirkstoff wenigstens ein salz von s-adenosyl-l- methionine. - Google Patents

Pharmazeutische zusammensetzung mit therapeutischer wirkung auf die neuronalen schädigungen in aids-patienten, enthaltend als wirkstoff wenigstens ein salz von s-adenosyl-l- methionine.

Info

Publication number
ATE199319T1
ATE199319T1 AT91117638T AT91117638T ATE199319T1 AT E199319 T1 ATE199319 T1 AT E199319T1 AT 91117638 T AT91117638 T AT 91117638T AT 91117638 T AT91117638 T AT 91117638T AT E199319 T1 ATE199319 T1 AT E199319T1
Authority
AT
Austria
Prior art keywords
adenosyl
methionine
salt
pharmaceutical composition
active ingredient
Prior art date
Application number
AT91117638T
Other languages
English (en)
Inventor
Greca Pietro La
Original Assignee
Knoll Farmaceutici S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll Farmaceutici S P A filed Critical Knoll Farmaceutici S P A
Application granted granted Critical
Publication of ATE199319T1 publication Critical patent/ATE199319T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT91117638T 1990-10-23 1991-10-15 Pharmazeutische zusammensetzung mit therapeutischer wirkung auf die neuronalen schädigungen in aids-patienten, enthaltend als wirkstoff wenigstens ein salz von s-adenosyl-l- methionine. ATE199319T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT02183390A IT1243859B (it) 1990-10-23 1990-10-23 Composizioni farmaceutiche comprendenti associazioni fra sali di s-adenosil-l-metionina e acido 5-metil (o 5-formil)-tetraidrofolico per la terapia di complicanze neurologiche negli ammalati di aids.

Publications (1)

Publication Number Publication Date
ATE199319T1 true ATE199319T1 (de) 2001-03-15

Family

ID=11187495

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91117638T ATE199319T1 (de) 1990-10-23 1991-10-15 Pharmazeutische zusammensetzung mit therapeutischer wirkung auf die neuronalen schädigungen in aids-patienten, enthaltend als wirkstoff wenigstens ein salz von s-adenosyl-l- methionine.

Country Status (13)

Country Link
US (1) US6093703A (de)
EP (1) EP0482493B1 (de)
JP (1) JP3289928B2 (de)
KR (1) KR100187992B1 (de)
AT (1) ATE199319T1 (de)
AU (1) AU645854B2 (de)
CA (1) CA2053826C (de)
DE (1) DE69132542T2 (de)
FI (1) FI914919L (de)
IT (1) IT1243859B (de)
NO (1) NO914157D0 (de)
PT (1) PT99300B (de)
ZA (1) ZA918355B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5660835A (en) * 1995-02-24 1997-08-26 East Carolina University Method of treating adenosine depletion
DK0877563T3 (da) * 1996-01-31 2004-07-26 Univ South Alabama Levnedsmiddel- og vitaminpræparater, der indeholder den naturlige isomer af reducerede folater
DE19628514C1 (de) * 1996-07-05 1997-09-25 E Dr Grundmann Kombination von S-Adenosylmethionin und Azidothymidin zur Hemmung der HIV-Replikation
DE19632823C1 (de) * 1996-08-14 1997-11-20 Symbio Herborn Group Gmbh & Co Komplexe zwischen S-(+)-Adenosylmethionin und 3'-Azido-2',3'-didesoxynucleosid als potente Inhibitoren der HIV-Replikation
US7071230B2 (en) 1997-10-02 2006-07-04 Board Of Trustees Of Southern Illinois University Therapeutic use of D-methionine to reduce the toxicity of noise
US8642581B1 (en) 2000-02-11 2014-02-04 Brian D. Halevie-Goldman Compositions and methods for the production of S-adenosylmethionine within the body
IT1317920B1 (it) * 2000-10-20 2003-07-15 Univ Roma S-adenosilmetionina e suoi derivati per il trattamento e laprevenzione della malattia di alzheimer.
US6759395B2 (en) 2000-12-18 2004-07-06 Orchid Chemicals & Pharmaceuticals, Ltd. Soft-gelatin capsule comprising S-adenosylmethionine and a method for producing the same
ITMI20012462A1 (it) * 2001-11-22 2003-05-22 Gnosis Srl Processo per la preparazione di compresse comprendenti s-adenosilmetionina
US20030155045A1 (en) * 2002-02-05 2003-08-21 Williams Peter C. Lubricated low temperature carburized stainless steel parts
DE602005026352D1 (de) * 2004-09-15 2011-03-31 Nipro Corp Wässrige, stabile (6S)-Folinsäurelösung zur Injektion
JP4956942B2 (ja) * 2004-09-15 2012-06-20 ニプロ株式会社 安定化された注射用水溶液製剤
ITMI20050485A1 (it) * 2005-03-23 2006-09-24 Truffini & Regge Farmaceutici Formulazioni granulari rivestite
FR2884421B1 (fr) 2005-04-15 2007-08-10 Virbac Sa Nouveaux moyens de regulation des troubles du comportement chez les animaux de compagnie
WO2006111541A2 (en) * 2005-04-20 2006-10-26 Basf Plant Science Gmbh Expression cassettes for seed-preferential expression in plants
WO2006119589A2 (en) * 2005-05-11 2006-11-16 Ramaekers, Vincent Prevention and therapy of cerebral folate deficiency
ITMI20060629A1 (it) 2006-03-31 2007-10-01 Daniele Giovannone Composizioni solide orali a base di s-adenosilmetionina e processo per il loro ottenimento
US20090088404A1 (en) * 2007-01-31 2009-04-02 Methylation Sciences International Srl Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
EP2189154A1 (de) * 2008-11-25 2010-05-26 Gnosis S.p.A. Efferveszenztabletten und im Mund lösliche Granulate aus S-Adenosy-Methionin und Herstellungsverfahren dafür
CN101862333B (zh) * 2009-04-20 2013-07-24 天津药物研究院 左亚叶酸钠稳定的口服制剂及其制备方法
US20110027342A1 (en) * 2009-07-28 2011-02-03 Msi Methylation Sciences, Inc. S-adenosylmethionine formulations with enhanced bioavailability
WO2012012902A1 (en) * 2010-07-28 2012-02-02 Msi Methylation Sciences Inc. S-adenosylmethionine formulations with enhanced bioavailability
US8329208B2 (en) * 2009-07-28 2012-12-11 Methylation Sciences International Srl Pharmacokinetics of S-adenosylmethionine formulations
US8372451B2 (en) * 2010-02-12 2013-02-12 Alexander Vuckovic, M.D., Llc Compositions and methods for treating depression
WO2014059522A1 (en) 2012-10-17 2014-04-24 Methylation Sciences International Srl Compositions comprising s-adenosylmethionine and a gallic acid ester
WO2016185413A1 (en) 2015-05-20 2016-11-24 Nestec S.A. Modified release formulations
WO2018144088A1 (en) 2016-11-03 2018-08-09 Alexander Vuckovic, M.D., Llc Compositions and methods for treating depression
KR20260020944A (ko) 2023-05-15 2026-02-12 보나파이드 헬스, 엘엘씨 수면 개선 조성물 및 이용 방법
EP4501315A1 (de) 2023-08-04 2025-02-05 Lesaffre et Compagnie Flüssige formulierungen von folaten

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1227049B (it) * 1988-07-29 1991-03-14 Bioresearch Spa Impiego di derivati adenosinici per la preparazione di composizioni farmaceutiche aventi attivita' immunostimolante.
GB8900812D0 (en) * 1989-01-14 1989-03-08 Univ Manchester Pharmaceutical method and compositions
EP0465460B1 (de) * 1989-02-09 1995-05-17 BARTON, Geoffrey James Prozessor zur signalverbesserung für stereosystem
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
DE4005275A1 (de) * 1990-02-20 1991-08-22 Grundmann Ewald Verwendung von s-adenosylmethionin als mittel gegen virale infektionen durch retroviren

Also Published As

Publication number Publication date
IT9021833A0 (it) 1990-10-23
AU645854B2 (en) 1994-01-27
EP0482493B1 (de) 2001-02-28
IT1243859B (it) 1994-06-28
PT99300B (pt) 1999-04-30
FI914919A7 (fi) 1992-04-24
CA2053826C (en) 2002-12-17
IT9021833A1 (it) 1992-04-23
KR920007629A (ko) 1992-05-27
EP0482493A3 (en) 1992-09-02
DE69132542T2 (de) 2001-06-21
US6093703A (en) 2000-07-25
JPH04264031A (ja) 1992-09-18
FI914919L (fi) 1992-04-24
ZA918355B (en) 1992-07-29
CA2053826A1 (en) 1992-04-24
NO914157D0 (no) 1991-10-23
EP0482493A2 (de) 1992-04-29
KR100187992B1 (ko) 1999-06-01
JP3289928B2 (ja) 2002-06-10
PT99300A (pt) 1992-08-31
AU8670891A (en) 1992-04-30
DE69132542D1 (de) 2001-04-05
FI914919A0 (fi) 1991-10-18

Similar Documents

Publication Publication Date Title
ATE199319T1 (de) Pharmazeutische zusammensetzung mit therapeutischer wirkung auf die neuronalen schädigungen in aids-patienten, enthaltend als wirkstoff wenigstens ein salz von s-adenosyl-l- methionine.
ZA928170B (en) Antiviral 4-substituted-2-deoxy-2,3-didehydro-derivatives of alpha-D-neuraminic acid
IL101883A0 (en) Antiviral combinations and pharmaceutical compositions containing them
DE59102210D1 (de) Galanthemin enthaltende pharmazeutische Formulierung zur Behandlung des Alkoholismus.
IT1211484B (it) Forma farmaceutica di dosaggio per somministrazione orale con erogazione controllata di un ingrediente attivo
AU4732989A (en) Pyrimidines and their pharmaceutical acceptable salts thereof, and their use as medicines
IL80149A (en) Pharmaceutical compositions containing toluidide derivatives against graft-versus-host diseases and autoimmune diseases
ES2160693T3 (es) Formulacion estable de 10-hidroxi-7-etil-camptotecina en la forma lactona.
PT615754E (pt) Formas solidas de administracao oral de libertacao controlada flupertina
DE69222698D1 (de) 4-desoxy-4-epipodophyllotoxinderivate oder deren pharmazeutisch akzeptierbaren salze
ATE38991T1 (de) In 2-stellung substituierte 1,3propyledendephosphonat-derivate, ihre herstellung und pharmazeutische zusammensetzungen, die sie enthalten.
ATE161531T1 (de) Acridine-1,8-dionderivate als therapeutisches mittel
GB8719670D0 (en) Pharmaceutical compositions
ES2169117T3 (es) Uso de derivados de 2-aminopurina en el tratamiento y profilaxis de la infeccion por el virus 7 del herpes humano.
ATE181828T1 (de) Oral anzuwendendes arzneimittel bestehend aus ibuprofen
ITMI913248A1 (it) Composizioni terapeutiche adatte per la somministrazione orale contenenti come principio attivo uno o piu' tioesteri del glutatione e procedimento per la preparazione dei suddetti principi attivi

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties